Related Experiment Video
Updated: Nov 7, 2025

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
Hospitalization Rates, Prevalence of Cardiovascular Manifestations and Outcomes Associated With Amyloidosis in the
Oreoluwa D Oladiran1, Adeolu O Oladunjoye2,3, Rashmi Dhital4
1Cardiology, Reading Hospital Tower Health, West Reading, USA.
Insights
Hospitalizations for amyloidosis, a multisystem disease, have increased, with a decrease in in-hospital deaths. However, cardiac amyloidosis remains linked to higher mortality, emphasizing the need for accessible screening.
Area of Science:
- Cardiology
- Hematology
- Epidemiology
Background:
- Amyloidosis is a multisystem disease involving precursor protein deposition in organs, notably the heart.
- Cardiac amyloidosis leads to significant morbidity and mortality, yet contemporary US data is limited.
- Understanding trends and outcomes of cardiac involvement in amyloidosis is crucial for patient care.
Purpose of the Study:
- To assess the prevalence and hospitalization trends of amyloidosis in the US.
- To evaluate outcomes, including in-hospital mortality, of cardiovascular manifestations in amyloidosis.
- To identify factors associated with in-hospital mortality in amyloidosis hospitalizations.
Main Methods:
- Retrospective analysis of the National (Nationwide) Inpatient Sample (NIS) database.
- Inclusion of adult hospitalizations from January 1, 2007, to December 31, 2014.
- Examination of hospitalization trends and outcomes stratified by cardiovascular comorbidities.
Main Results:
- A total of 137,797 amyloidosis hospitalizations were identified between 2007 and 2014.
- Amyloidosis hospitalizations increased significantly (34 to 73 per 100,000), with 63.2% having cardiovascular manifestations.
- In-hospital mortality decreased over the study period (8.4% to 6.8%), but cardiac involvement remained associated with higher mortality.
Conclusions:
- Amyloidosis hospitalizations have risen, accompanied by a decrease in in-hospital mortality.
- Cardiac amyloidosis continues to be associated with increased in-hospital mortality, even after adjusting for other factors.
- Enhanced screening for cardiovascular manifestations in amyloidosis patients is recommended to improve outcomes.
Abstract:
Background Amyloidosis is a multisystem disease characterized by the deposition of misfolded insoluble precursor protein fibrils in several organs including the heart. Cardiac amyloidosis can result in a wide range of complications that may lead to significant morbidity and mortality. However, contemporary data in the United States (US) on cardiac amyloidosis is scarce despite these negative consequences. In view of this lack of contemporary data, we sort to assess the prevalence, trends of hospitalization, and outcomes of cardiovascular manifestations in amyloidosis. We also explored this retrospective data for factors that may be associated with in-hospital mortality of amyloidosis hospitalization. Methods We used the national (nationwide) inpatient sample (NIS) database from January 1, 2007 - December 31, 2014, of adult hospitalizations. We studied the prevalence and trends of hospitalizations of amyloidosis among patient with or without cardiovascular co-morbidities. Results We identified 137,797 amyloidosis hospitalizations from 2007 to 2014 of which 87,164 (63.2%) had cardiovascular manifestations. The overall mean age was 70.3±12 years. There were more males (54.5%) overall. The trend of amyloidosis hospitalizations increased significantly from 2007 through 2014 (34 to 73 per 100,000, Ptrend <0.001) and in-hospital mortality decreased from 8.4 to 6.8 per 100 amyloidosis hospitalizations, Ptrend <0.001). Conclusion Our study showed that hospitalizations of amyloidosis have increased considerably over the past decades with a concurrent decline in in-hospital mortality. Despite this decline and after adjusting for other factors, amyloidosis hospitalization with cardiovascular manifestations was still associated with higher in-hospital mortality. Screening of patients with amyloidosis for cardiovascular manifestations should be more accessible to prevent undesired outcomes.
More Related Videos
09:31Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
10:04Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
Published on: October 20, 2017
Related Concept Videos
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Amyloid Fibrils
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Cardiomyopathy V: Interprofessional Care
Coronary Artery Disease III: Clinical Manifestations
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...